LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced <em>RET</em> Fusion-Positive (<em>RET</em>+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC

Commentary

LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC

Total article views		HTML views	PDF downloads	Totals
857	Dovepress*	845+	22	867
	PubMed Central*	12	8	20
	Totals	857	30	887
*Since 23 May 2024

Total mentioned	Facebook	Delicious	Reddit	Twitter	Others
4	0	0	2	0	2